Defined Terms Location. Celgene Licensed Product In-Licensed IP Section 1.9 Celgene Licensed Product IP Section 1.10 Celgene Other In-License Section 1.11 Celgene Regulatory Rights Section 1.12 Celgene Technology Section 1.13 Clinical Data Section 8 Clinical Study Section 1.14 Combination Product Section 1.29 Commercialization Section 1.15 Commercially Reasonable Efforts Section 1.16 Competitive Infringement Section 7.1 Control Section 1.17 Covers Section 1.18 Elected Candidate Appendix A EU Section 1.19 Eurogentec Section 2.4(b)(ii)(B) Field Section 1.20 First Commercial Sale Section 1.21 First Indication Section 1.22 Fully Burdened Manufacturing Cost Appendix H GAAP Section 1.23 Gene Editing Section 1.24 Independent Target Antigen Program Section 3.4 In-License Payment Section 1.25 Indemnification Claim Notice Section 9.6(c) Indemnified Party Section 9.6(c) Joint IP Section 5.2 License Agreement Preamble License Agreement Term Section 10.1 Licensed IP Section 1.26 Licensed Product Section 1.27 Litigation Conditions Section 9.6(d)(i) Losses Section 9.6(a) Manufacturing Section 1.28 Manufacturing Party 2.4(b)(i)(E) Manufacturing and Supply Agreement Section 2.4(b)(i)(B) Master Collaboration Agreement Preamble Milestone Event Section 4.2 Milestone Payment Section 4.2 Modified Licensed Product Section 1.27 Net Sales Section 1.29 Original MCA Preamble Original License Agreement Effective Date Preamble Party(ies) Preamble Patent Challenge Section 10.2(b) PHSA Section 7.2(f) Pivotal Study Section 1.30 Regulatory Exclusivity Period Section 1.31 Second Indication Section 1.32 Selling Party Section 1.35 Solely Owned IP Section 5.1 Specific Patent Section 6.3 Sublicensee Section 1.36 Suspension Transition Plan Section 2.4(b)(i)(A) Third Party Claims Section 9.6(a) Valid Claim Section 1.38 Vector Supplies Section 1.40
Defined Terms Location. Additional Bluebird IP Section 10.7(a) Allowable Expenses Appendix F Allocable Manufacturing Overhead Appendix D Allocable Overhead Appendix F [***] [***] Bluebird Indemnitees Section 11.6(a) Budgeted U.S. Development Costs Section 4.3 Business Acquisition Section 10.4 Business Party Section 10.4 Business Program Section 10.4 CCPS Agreement Term Section 12.1 Celgene Indemnitees Section 11.6(b) CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Commercial Supplies Appendix D Competitive Infringement Section 14.1 [***] Cost of Goods Sold or COGS Appendix F [***] Development & U.S. Commercialization Program Section 8.3(a) Distribution Costs Appendix F Elected Candidate Appendix A Fully Burdened Manufacturing Cost Appendix D Gross Profit Appendix F Gross Sales Appendix F Indemnification Claim Notice Section 11.6(c) Indemnified Party Section 11.6(c) Information Request Section 5.6(g) JGC Section 3.1(a) Joint IP Section 12.2 Losses Section 11.6(a) Major EU Countries Section 1.21 Manufacturing and Supply Agreement Section 7.4(b)(ii) Marketing Costs Appendix F Milestone Event Section 11.2(a) Milestone Payment Section 11.2(a) Modified Licensed Product Section 1.24 [***] Operating Profits or Losses Appendix F Other Operating Income/Expense Appendix F Profit & Loss Share Section 11.4 ROW Post-Approval Manufacturing Plan Section 7.3 Sales Costs Appendix F Sales Returns and Allowances Appendix F Solely Owned IP Section 12.1 Specific Patent Section 13.3 Third Party Claims Section 11.6(a) U.S. Administration Liabilities Section 16.8 U.S. Development Costs Appendix F
Defined Terms Location. Additional IP Section 3.2(a) Allocable Manufacturing Overhead Appendix D [***] Biosimilar Product Competition Section 4.3(e) Bluebird Indemnitees Section 9.6(a) Business Acquisition Section 3.4 Business Party Section 3.4 Business Program Section 3.4 Celgene Indemnitees Section 9.6(b) Commercial Supplies Appendix D Competitive Infringement Section 7.1 Elected Candidate Appendix A Fully Burdened Manufacturing Cost Appendix D Indemnification Claim Notice Section 9.6(c) Indemnified Party Section 9.6(c) Joint IP Section 5.2 License Agreement Term Section 10.1 Losses Section 9.6(a) Major EU Countries Section 1.18 Manufacturing and Supply Agreement Section 2.4(c)(ii) Milestone Event Section 4.2 Milestone Payment Section 4.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
Defined Terms Location. Solely Owned IP Section 5.1 Specific Patent Section 6.3 Sublicensee Section 1.35 Third Party Claims Section 9.6(a) Valid Claim Section 1.37 Vector Supplies Section 1.38
Defined Terms Location. Modified Licensed Product Section 1.21 [***] Solely Owned IP Section 5.1 Third Party Claims Section 9.6(a)
Defined Terms Location. Additional IP Section 3.2(a) Additional Payments Section 1.17
Defined Terms Location. Milestone Event Section 4.2 Milestone Payment Section 4.2 Modified Licensed Product Section 1.28 Net Sales Section 1.30 Original MCA Preamble Party(ies) Preamble Patent Challenge Section 10.2(b) PHSA Section 7.2(f) Pivotal Study Section 1.31 Regulatory Exclusivity Period Section 1.32 Second Indication Section 1.33 Selling Party Section 1.34 Solely Owned IP Section 5.1 Specific Patent Section 6.3 Sublicensee Section 1.35 Third Party Claims Section 9.6(a) Valid Claim Section 1.37 Vector Supplies Section 1.38
Defined Terms Location. Net Sales Section 1.30 Original MCA Preamble Party(ies) Preamble Patent Challenge Section 10.2(b) PHSA Section 7.2(f) Pivotal Study Section 1.31 Regulatory Exclusivity Period Section 1.32 Second Indication Section 1.33 Selling Party Section 1.34 Solely Owned IP Section 5.1 Specific Patent Section 6.3 Sublicensee Section 1.35 Third Party Claims Section 9.6(a) Valid Claim Section 1.37 Vector Supplies Section 1.38
Defined Terms Location. Additional Bluebird IP Section 10.7(a) Additional Payments Section 1.19 Allowable Expenses Appendix F Allocable Overhead Appendix F Applicable Bluebird In-License Section 1.1 Applicable New In-License Section 1.2 Applicable Pre-Existing In-License Section 1.3 Biosimilar Application Section 14.2(f) Biosimilar Product Section 1.4
Defined Terms Location. Modified Licensed Product Section 1.30 Net Sales Section 1.32 Operating Profits or Losses Appendix F Original MCA Preamble Other Operating Income/Expense Appendix F Party(ies) Preamble Profit & Loss Share Section 11.4 Pivotal Study Section 1.33 Regulatory Exclusivity Period Section 1.34 ROW Section 1.35 ROW Administration Section 1.36 ROW Development & Commercialization Program Section 1.37 ROW Development Plan Section 1.38 ROW Post-Approval Manufacturing Plan Section 7.3 Sales Costs Appendix F Sales Returns and Allowances Appendix F Second Indication Section 1.39 Solely Owned IP Section 12.1 Selling Party Section 1.40 Specific Patent Section 13.3 Sublicensee Section 1.41 Target Antigen Section 1.42 Third Party Claims Section 16.6(a) U.S. Administration Section 1.43 U.S. Administration Liabilities Section 16.8 U.S. Commercialization Budget Section 1.44 U.S. Commercialization Plan Section 1.45 U.S. Development Budget Section 1.46 U.S. Development Costs Appendix F U.S. Development Plan Section 1.47 U.S. Development & Commercialization Program Section 1.48 Valid Claim Section 1.49 Vector Supplies Section 1.50 Worldwide Commercialization Plan Section 1.51 Worldwide Manufacturing Plan Section 1.52
